Company intelligence / Profile preview
Incyclix Bio
Research Triangle Park, North Carolina, United Statesincyclixbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
INX-315, the company's lead CDK2 inhibitor, has received FDA Fast Track designation for treating CCNE1-amplified platinum-resistant/refractory ovarian cancer. It is currently in a Phase 1/2 clinical trial evaluating safety, tolerability, pharmacokinetics, and preliminary antitumor activity in patients with recurrent advanced/metastatic cancer.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Incyclix Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Incyclix Bio.